GRAIL Announces The First Patient Has Been Tested For Eligibility With Its Non-Small Cell Lung Cancer CtDNA Assay In The TROPION-Lung12 Phase 3 Study, Sponsored By AstraZeneca In Collaboration With Daiichi Sankyo
GRAIL Announces The First Patient Has Been Tested For Eligibility With Its Non-Small Cell Lung Cancer CtDNA Assay In The TROPION-Lung12 Phase 3 Study, Sponsored By AstraZeneca In Collaboration With Daiichi Sankyo
GRAIL 宣佈第一位患者已通過其非小細胞肺癌 ctDNA 檢測，在阿斯利康與大冢製藥合作贊助的 TROPION-Lung12 III 期研究中進行資格測試。
GRAIL Announces The First Patient Has Been Tested For Eligibility With Its Non-Small Cell Lung Cancer CtDNA Assay In The TROPION-Lung12 Phase 3 Study, Sponsored By AstraZeneca In Collaboration With Daiichi Sankyo
GRAIL宣佈，第一個患者已在阿斯利康與第一三共合作的TROPION-Lung12 3期研究中，接受其非小細胞肺癌CtDNA檢測的資格測試。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間